Breast cancer stem cells: An overview
European Journal of Cancer, ISSN: 0959-8049, Vol: 42, Issue: 9, Page: 1219-1224
2006
- 119Citations
- 132Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations119
- Citation Indexes119
- 119
- CrossRef101
- Captures132
- Readers132
- 132
Article Description
The theory that cancer may be originated and sustained by a small proportion of stem-like, self-renewing cells (termed ‘cancer stem cells’) has gained support in recent years. Breast cancer stem cells have been identified as CD44 + CD24 − breast tumour cells and have recently been isolated and propagated in vitro. It has been demonstrated that these cells exclusively retain the ability to form new tumours in mouse models and that they display stem/progenitor cell properties. The ability to identify breast cancer stem cells in vivo and to propagate them in vitro provides the means to compare them with normal cells, in order to investigate from which cell they originate, which molecular alterations critically affect them, and how they interact with the microenvironment. Elucidation of these critical points is essential to develop new therapeutic strategies and to improve diagnosis and prognosis for breast cancer patients.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0959804906001791; http://dx.doi.org/10.1016/j.ejca.2006.01.031; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33646938749&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/16624548; https://linkinghub.elsevier.com/retrieve/pii/S0959804906001791; https://dx.doi.org/10.1016/j.ejca.2006.01.031
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know